INDUSTRY × Laryngeal Neoplasms × Clear all
NCT05461430 2025-09-15

TraveraRTGx

Travera Inc

Recruiting
200 enrolled
NCT05179824 2025-05-06

Tempus Priority Study: A Pan-tumor Observational Study

Tempus AI

Active not recruiting
1,000 enrolled
NCT04985357 2024-11-25

Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs

Travera Inc

Withdrawn
NCT03329950 2024-03-28

A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies

Celldex Therapeutics

Phase 1 Completed
132 enrolled
NCT03602079 2023-08-03

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Klus Pharma Inc.

Phase 1/2 Completed
49 enrolled
NCT03896958 2020-12-04

PIONEER

SpeciCare

Unknown
1,000 enrolled